Daré Bioscience’s (DARE) Buy Rating Reaffirmed at HC Wainwright

Daré Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 273.83% from the company’s previous close.

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a report on Wednesday, August 14th.

Daré Bioscience Price Performance

Shares of NASDAQ:DARE opened at $3.21 on Friday. The stock has a market cap of $27.45 million, a P/E ratio of -2.86 and a beta of 1.34. Daré Bioscience has a 1-year low of $3.05 and a 1-year high of $7.56. The firm has a fifty day moving average price of $3.56 and a 200 day moving average price of $3.92.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC raised its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is owned by hedge funds and other institutional investors.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.